Boehringer Ingelheim International Gmbh

Boehringer Ingelheim (canada) Ltd.

Boehringer Ingelheim Gmbh

Sylvie Goulet

Jean Rancourt

Pierre Louis Beaulieu

Martin Poirier

Youla S Tsantrizos

George Kukolj

Gulrez Fazal

Montse Llinas-Brunet

Murray D Bailey

Teddy Halmos

Nathalie Goudreau

Elise Ghiro

James Gillard

Pasquale Forgione

Punit R Bhardwaj

Vida J Gorys

Josee Bordeleau

Marc-André Poupart

Eric Jolicoeur

Christiane Yoakim

Martin Duplessis

Marc-Andre Poupart

Bounkham Thavonekham

Patrick Deroy

Alexandre Gagnon

Oliver Hucke

Simon Suprenant

René Coulombe

Christopher Lemke

Tim Stammers

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

The present invention relates to compounds of formula (I) wherein R, R, Rand Rare as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection. 

Inhibitors of HIV replication

Compounds of formula I: wherein X, R, R, Rand Rare defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Viral polymerase inhibitors

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: wherein Rand Rand Q are as defined herein;

An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I:wherein Ris selected from: H, haloalkyl, (C)alkyl, (C)alkenyl, (C)cycloalkyl, (C)alkynyl, (C)cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted;

Growing community of inventors

Pierrefonds, Canada

Sylvie Goulet